(Q46921326)

26 December 2017

title

Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab (English)

1 reference

26 December 2017

author name string

A A Vo

1

1 reference

26 December 2017

E A Wechsler

2

1 reference

26 December 2017

J Wang

3

1 reference

26 December 2017

A Peng

4

1 reference

26 December 2017

M Toyoda

5

1 reference

26 December 2017

M Lukovsky

6

1 reference

26 December 2017

N Reinsmoen

7

1 reference

26 December 2017

S C Jordan

8

1 reference

26 December 2017

language of work or name

English

0 references

publication date

31 October 2007

1 reference

26 December 2017

American Journal of Transplantation

published in

1 reference

26 December 2017

volume

8

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

144-149

1 reference

26 December 2017

Antibody-mediated organ-allograft rejection

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

National conference to assess antibody-mediated rejection in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Presensitization: the problem and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Current approaches to treatment of antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.02017.X

10.1111/J.1600-6143.2007.02017.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017